Company record · updated August 5, 2026
Finch Therapeutics Group, Inc.: 5 valuation observations from SEC filings
Every row below names the filing it came from. Coverage for this company runs February 26, 2021 to March 15, 2021.
5observations
2source filings
5verified rows
2021-03-15most recent as-of date
Source rails for this company: S-1 charter round (5).
| As of | Measure | Value | Reported by | Tier | What the filing says | Accession |
|---|---|---|---|---|---|---|
| 2021-03-15 | Series D price per share | 13.038 USD | — | VERIFIED | "Original Issue Price" defined for Series D | 000119312521080450 |
| 2021-03-15 | Series C price per share | 13.038 USD | — | VERIFIED | "Original Issue Price" defined for Series C | 000119312521080450 |
| 2021-03-15 | Series B price per share | 7.0458 USD | — | VERIFIED | "Original Issue Price" defined for Series B | 000119312521080450 |
| 2021-03-15 | Series A price per share | 7.0458 USD | — | VERIFIED | "Original Issue Price" defined for Series A | 000119312521080450 |
| 2021-02-26 | Series A price per share | 0.2395 USD | — | VERIFIED | "Original Issue Price" defined for Series A | 000119312521060632 |
Reading these figures
A fund mark is the filer's own fair-value estimate at a quarter end, not a transaction price, and two filers can reach different values for the same date. A charter round price is the issue price of that series at issuance. Neither is a current market price. The capabilities page states the full limits.